Crinetics Pharmaceuticals Inc (CRNX)
56.82
+0.13
(+0.23%)
USD |
NASDAQ |
Nov 04, 16:00
56.82
0.00 (0.00%)
After-Hours: 20:00
Crinetics Pharmaceuticals Enterprise Value: 3.674B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 3.674B |
| October 31, 2024 | 3.616B |
| October 30, 2024 | 3.600B |
| October 29, 2024 | 3.640B |
| October 28, 2024 | 3.711B |
| October 25, 2024 | 3.776B |
| October 24, 2024 | 3.838B |
| October 23, 2024 | 3.811B |
| October 22, 2024 | 3.908B |
| October 21, 2024 | 3.835B |
| October 18, 2024 | 3.866B |
| October 17, 2024 | 3.853B |
| October 16, 2024 | 3.848B |
| October 15, 2024 | 3.747B |
| October 14, 2024 | 3.387B |
| October 11, 2024 | 3.390B |
| October 10, 2024 | 3.281B |
| October 09, 2024 | 3.195B |
| October 08, 2024 | 3.275B |
| October 07, 2024 | 3.280B |
| October 04, 2024 | 3.390B |
| October 03, 2024 | 3.361B |
| October 02, 2024 | 3.461B |
| October 01, 2024 | 3.292B |
| September 30, 2024 | 3.227B |
| Date | Value |
|---|---|
| September 27, 2024 | 3.199B |
| September 26, 2024 | 3.185B |
| September 25, 2024 | 3.175B |
| September 24, 2024 | 3.124B |
| September 23, 2024 | 3.172B |
| September 20, 2024 | 3.391B |
| September 19, 2024 | 3.449B |
| September 18, 2024 | 3.361B |
| September 17, 2024 | 3.378B |
| September 16, 2024 | 3.454B |
| September 13, 2024 | 3.443B |
| September 12, 2024 | 3.237B |
| September 11, 2024 | 3.198B |
| September 10, 2024 | 3.171B |
| September 09, 2024 | 3.318B |
| September 06, 2024 | 3.170B |
| September 05, 2024 | 3.217B |
| September 04, 2024 | 3.363B |
| September 03, 2024 | 3.300B |
| August 30, 2024 | 3.384B |
| August 29, 2024 | 3.355B |
| August 28, 2024 | 3.491B |
| August 27, 2024 | 3.497B |
| August 26, 2024 | 3.389B |
| August 23, 2024 | 3.391B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
164.62M
Minimum
Mar 16 2020
3.908B
Maximum
Oct 22 2024
1.007B
Average
624.66M
Median
Enterprise Value Benchmarks
| PTC Therapeutics Inc | 2.305B |
| Zevra Therapeutics Inc | 451.06M |
| Clearside Biomedical Inc | 46.13M |
| Biomea Fusion Inc | 239.65M |
| NovaBay Pharmaceuticals Inc | 3.615M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -74.06M |
| Revenue (Quarterly) | 0.399M |
| Total Expenses (Quarterly) | 83.18M |
| EPS Diluted (Quarterly) | -0.94 |
| Profit Margin (Quarterly) | -18.56K% |
| Earnings Yield | -6.65% |
| Normalized Earnings Yield | -6.653 |